Takeda Pharmaceutical Company Limited(TAK) Stock Research - Grey Stern Research
Loading...

Takeda Pharmaceutical Company Limited (TAK) Stock Analysis

$13.76 (-3.27%)

TAK Financial Performance


Use the table below to view Takeda Pharmaceutical Company Limited's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2025

Metric Value Ranking among Peers
Price $14.05 -
52 Week Low $12.58 -
52 Week High $15.08 -
Market Cap $44.5 Billion 2/18
Gross Margin 54% 10/18
Profit Margin 8% 7/18
EBITDA margin 34% 4/18
Q1 - 2025 Revenue $8.5 Billion 1/18
Q1 - 2025 Earnings $666.5 Million 1/18
Q1 - 2025 Free Cash Flow $151.0 Million 5/18
Trailing 4 Quarters Revenue $30.9 Billion 1/18
Trailing 4 Quarters Earnings $1.0 Billion 2/18
Quarterly Earnings Growth 7% 7/18
Annual Earnings Growth -18% 13/18
Quarterly Revenue Growth 14% 7/18
Annual Revenue Growth 12% 8/18
Cash On Hand $5.6 Billion 1/18
Short Term Debt $3.1 Billion 1/18
Long Term Debt $35.3 Billion 1/18

Takeda Pharmaceutical Company Limited Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Takeda Pharmaceutical Company Limited's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 42.46 2/18
PS 206.11 1/18
PB 0.82 14/18
PC 7.91 11/18
Liabilities to Equity 1.08 10/18
ROA 0.00 9/18
ROE 0.00 12/18
Current Ratio 1.93 7/18
Quick Ratio 0.10 10/18
Long Term Debt to Equity 0.65 10/18
Debt to Equity 0.70 11/18
Burn Rate 2.59 4/18
Cash to Cap 0.13 8/18
CCR 0.23 10/18
EV to EBITDA 11.35 15/18
EV to Revenue 151.44 1/18

Company Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

CEO: Mr. Christophe Weber

Website: https://www.takeda.com

Address: 1-1, Nihonbashi-Honcho 2-chome Tokyo,

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—Specialty & Generic

Takeda Pharmaceutical Company Limited Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Takeda Pharmaceutical Company Limited. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Teva Pharmaceutical Industries Limited TEVA $21.3 Billion
Prestige Consumer Healthcare Inc. PBH $3.7 Billion
Zoetis Inc. ZTS $79.4 Billion
Pacira BioSciences, Inc. PCRX $797.1 Million
Esperion Therapeutics, Inc. ESPR $416.0 Million
Neurocrine Biosciences, Inc. NBIX $12.3 Billion
Collegium Pharmaceutical, Inc. COLL $1.1 Billion
Eagle Pharmaceuticals, Inc. EGRX $11.0 Million
Catalent, Inc. CTLT $10.6 Billion
Emergent BioSolutions Inc. EBS $484.0 Million
Amphastar Pharmaceuticals, Inc. AMPH $2.5 Billion
Phibro Animal Health Corporation PAHC $925.5 Million
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Bausch Health Companies Inc. BHC $3.6 Billion
Elanco Animal Health Incorporated ELAN $6.3 Billion
SIGA Technologies, Inc. SIGA $516.7 Million
Viatris Inc. VTRS $13.9 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TAK Income Statements
Quarter Year Revenue Earnings
Q1 2025 ¥ 1.2 Trillion ¥95.2 Billion
Q4 2024 ¥ 1.1 Trillion -¥3.0 Billion
Q3 2024 ¥ 1.1 Trillion ¥105.7 Billion
Q2 2024 ¥ 1.0 Trillion -¥48.0 Billion
Q1 2024 ¥ 1.1 Trillion ¥89.4 Billion
Q4 2023 ¥ 956.2 Billion ¥31.1 Billion
Q3 2023 ¥ 1.1 Trillion ¥119.1 Billion
Q2 2023 ¥ 1.0 Trillion ¥61.7 Billion

View All

TAK Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2025 ¥804.3 Billion ¥16.2 Trillion ¥5.5 Trillion ¥7.8 Trillion
Q4 2024 ¥457.8 Billion ¥15.1 Trillion ¥4.8 Trillion ¥7.3 Trillion
Q3 2024 ¥288.4 Billion ¥14.2 Trillion ¥4.7 Trillion ¥6.7 Trillion
Q2 2024 ¥318.1 Billion ¥14.9 Trillion ¥4.7 Trillion ¥7.1 Trillion
Q1 2024 ¥316.4 Billion ¥14.8 Trillion ¥4.7 Trillion ¥6.9 Trillion
Q4 2023 ¥533.5 Billion ¥14.0 Trillion ¥4.4 Trillion ¥6.4 Trillion
Q3 2023 ¥685.1 Billion ¥13.5 Trillion ¥4.3 Trillion ¥6.2 Trillion
Q2 2023 ¥798.1 Billion ¥14.6 Trillion ¥4.7 Trillion ¥6.7 Trillion

View All

TAK Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2025 ¥21.6 Billion -¥137.8 Billion ¥599.1 Billion
Q4 2024 ¥208.1 Billion -¥64.3 Billion ¥169.4 Billion
Q3 2024 ¥69.3 Billion -¥77.1 Billion -¥29.7 Billion
Q2 2024 ¥128.9 Billion -¥70.0 Billion ¥1.7 Billion
Q1 2024 -¥176.8 Billion -¥269.2 Billion -¥217.2 Billion
Q4 2023 -¥150.4 Billion -¥444.1 Billion -¥151.6 Billion
Q3 2023 ¥327.6 Billion -¥50.6 Billion -¥113.0 Billion
Q2 2023 ¥180.4 Billion -¥40.6 Billion ¥152.1 Billion

View All